BioMed Research International / 2014 / Article / Tab 6

Clinical Study

Clinical Study of Nasopharyngeal Carcinoma Treated by Helical Tomotherapy in China: 5-Year Outcomes

Table 6

Log-rank test for univariate analysis.

Factor3-year LRFS3-year NRFS3-year DMFS3-year OS

Age (y)
 ≤5094.8% 94.8% 91.5% 83.1%
 >5080.8%100.0%70.4%58.8%
Gender
 Male93.7% 96.8% 82.1% 74.0%
 Female81.0%94.4%94.7%77.3%
T Stage
 T188.9% 100.0% 89.5% 81.0%
 T297.7%100.0%87.0%85.1%
 T380.0%80.0%77.8%53.8%
 T470.5%90.9%75.0%55.6%
N Stage
 N085.7% 100.0% 100.0% 85.7%
 N190.0%100.0%72.7%70.3%
 N292.6%92.9%86.2%73.5%
 N3100.0%83.3%100.0%71.4%
Node category
 N+85.7% 100.0% 100.0% 85.7%
 N−92.1%95.2%80.9%71.8%
UICC Stage
 I83.3% 100.0% 100.0% 82.5%
 II100.0%100.0%82.1%85.0%
 III86.7%93.1%83.3%96.4%
 IV80.0%90.9%91.7%66.7%
IGRT and GTVnx to pGTVnx margin
 Every day and 5 mm92.5% 100% 86.8% 81.1%
 Every week and 3 mm96.8%97.9%93.7%86.3%
Chemotherapy was performed or not in stage III-IV patients
 No57.1% 100.0% 57.1% 55.6%
 Yes90.0%92.1%90.0%71.7%
Concurrent chemotherapy was performed or not in stage III-IV patients
 No81.5% 91.7% 81.5% 70.0%
 Yes90.0%94.7%90.0%68.0%
Anti-EGFR monoclonal antibody was used or not in stage III-IV patients
 No84.0% 91.3% 84.0% 65.6%
 Yes86.4%     95.0%     86.4%     73.9%